Last reviewed · How we verify
Split virion, inactivated Influenza vaccine
Split virion, inactivated Influenza vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 2 development.
At a glance
| Generic name | Split virion, inactivated Influenza vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (PHASE3)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- Clinical Trials of Quadrivalent Influenza Vaccine (PHASE1, PHASE2)
- Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children . (PHASE3)
- Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older (PHASE3)
- Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older (PHASE3)
- Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Split virion, inactivated Influenza vaccine CI brief — competitive landscape report
- Split virion, inactivated Influenza vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Split virion, inactivated Influenza vaccine
What is Split virion, inactivated Influenza vaccine?
Split virion, inactivated Influenza vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Split virion, inactivated Influenza vaccine?
Split virion, inactivated Influenza vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
What development phase is Split virion, inactivated Influenza vaccine in?
Split virion, inactivated Influenza vaccine is in Phase 2.